Dysregulated Alternative Splicing Landscape Identifies Intron Retention as a Hallmark and Spliceosome as a Therapeutic Vulnerability in Aggressive Prostate Cancer

Dysregulation of mRNA alternative splicing (AS) has been implicated in development and progression of hematological malignancies. Here we describe the first comprehensive AS landscape in the spectrum of human prostate cancer (PCa) development, progression and therapy resistance. We find that the severity of splicing dysregulation correlates with disease progression and establish intron retention (IR) as a hallmark of PCa stemness and aggressiveness. Systematic interrogation of 274 splicing-regulatory genes (SRGs) uncovers prevalent SRG mutations associated with, mainly, copy number variations leading to mis-expression of ~68% of SRGs during PCa evolution. Consequently, we identify many SRGs as prognostic markers associated with splicing disruption and patient outcome. Interestingly, androgen receptor (AR) controls a splicing program distinct from its transcriptional regulation. The spliceosome modulator, E7107, reverses cancer aggressiveness and abolishes the growth of castration-resistant PCa (CRPC) models. Altogether, we establish aberrant AS landscape caused by dysregulated SRGs as a novel therapeutic vulnerability for CRPC. Statement of significance We present the first comprehensive AS landscape during PCa evolution and link genomic and transcriptional alterations in SRGs to global splicing dysregulation. AR regulates splicing in pri-PCa and CRPC distinct from its transcriptional regulation. Intron retention is a hallmark for and spliceosome represents a therapeutic vulnerability in aggressive PCa.

[1]  Shuhong Zhao,et al.  Prostate Luminal Progenitor Cells in Development and Cancer. , 2018, Trends in cancer.

[2]  D. Tang,et al.  Cancer stem cells: Regulation programs, immunological properties and immunotherapy. , 2018, Seminars in cancer biology.

[3]  A. Gavin,et al.  Impact of spliceosome mutations on RNA splicing in myelodysplasia: dysregulated genes/pathways and clinical associations. , 2018, Blood.

[4]  M. Rubin,et al.  Linking prostate cancer cell AR heterogeneity to distinct castration and enzalutamide responses , 2018, Nature Communications.

[5]  Feixiang Wu,et al.  RBM38 plays a tumor-suppressor role via stabilizing the p53-mdm2 loop function in hepatocellular carcinoma , 2018, Journal of experimental & clinical cancer research : CR.

[6]  D. Tang,et al.  “Splice” a way towards neuroendocrine prostate cancer , 2018, EBioMedicine.

[7]  S. Lowe,et al.  Nuclear Pores Promote Lethal Prostate Cancer by Increasing POM121-Driven E2F1, MYC, and AR Nuclear Import , 2018, Cell.

[8]  Jun Luo,et al.  Alternative splicing in prostate cancer , 2018, Nature Reviews Clinical Oncology.

[9]  Steven J. M. Jones,et al.  Comprehensive Analysis of Alternative Splicing Across Tumors from 8,705 Patients , 2018, Cancer cell.

[10]  Ping Zhu,et al.  Somatic Mutational Landscape of Splicing Factor Genes and Their Functional Consequences across 33 Cancer Types. , 2018, Cell reports.

[11]  Y. Xing,et al.  The Expanding Landscape of Alternative Splicing Variation in Human Populations , 2018, American journal of human genetics.

[12]  Yue Lu,et al.  Histone 2B-GFP Label-Retaining Prostate Luminal Cells Possess Progenitor Cell Properties and Are Intrinsically Resistant to Castration , 2017, Stem cell reports.

[13]  Michael C. Ryan,et al.  Revealing the Determinants of Widespread Alternative Splicing Perturbation in Cancer. , 2017, Cell reports.

[14]  Y. Homma,et al.  Dysregulation of spliceosome gene expression in advanced prostate cancer by RNA-binding protein PSF , 2017, Proceedings of the National Academy of Sciences.

[15]  Adam Godzik,et al.  The Functional Impact of Alternative Splicing in Cancer. , 2017, Cell reports.

[16]  Antoine de Weck,et al.  Project DRIVE: A Compendium of Cancer Dependencies and Synthetic Lethal Relationships Uncovered by Large-Scale, Deep RNAi Screening , 2017, Cell.

[17]  Phillip G. Montgomery,et al.  Defining a Cancer Dependency Map , 2017, Cell.

[18]  S. Knapp,et al.  Alternative splicing promotes tumour aggressiveness and drug resistance in African American prostate cancer , 2017, Nature Communications.

[19]  M. Loda,et al.  Genome-wide CRISPR screen identifies HNRNPL as a prostate cancer dependency regulating RNA splicing , 2017, Proceedings of the National Academy of Sciences.

[20]  C. Sette,et al.  An Orchestrated Intron Retention Program in Meiosis Controls Timely Usage of Transcripts during Germ Cell Differentiation , 2017, Developmental cell.

[21]  E. Eyras,et al.  IRFinder: assessing the impact of intron retention on mammalian gene expression , 2017, Genome Biology.

[22]  Rob Patro,et al.  Salmon provides fast and bias-aware quantification of transcript expression , 2017, Nature Methods.

[23]  C. Collins,et al.  Alternative RNA splicing of the MEAF6 gene facilitates neuroendocrine prostate cancer progression , 2017, Oncotarget.

[24]  O. Mühlemann,et al.  Transcriptome-wide identification of NMD-targeted human mRNAs reveals extensive redundancy between SMG6- and SMG7-mediated degradation pathways , 2017, RNA.

[25]  Henry W. Long,et al.  Rb1 and Trp53 cooperate to suppress prostate cancer lineage plasticity, metastasis, and antiandrogen resistance , 2017, Science.

[26]  M. Rubin,et al.  SOX2 promotes lineage plasticity and antiandrogen resistance in TP53- and RB1-deficient prostate cancer , 2017, Science.

[27]  Omar Abdel-Wahab,et al.  Therapeutic targeting of splicing in cancer , 2016, Nature Medicine.

[28]  K. Kalland,et al.  Context dependent regulatory patterns of the androgen receptor and androgen receptor target genes , 2016, BMC Cancer.

[29]  Kairong Cui,et al.  Global intron retention mediated gene regulation during CD4+ T cell activation , 2016, Nucleic acids research.

[30]  Peter Ulz,et al.  Whole-genome plasma sequencing reveals focal amplifications as a driving force in metastatic prostate cancer , 2016, Nature Communications.

[31]  R. Lothe,et al.  Aberrant RNA splicing in cancer; expression changes and driver mutations of splicing factor genes , 2016, Oncogene.

[32]  J. Valcárcel,et al.  Large-scale analysis of genome and transcriptome alterations in multiple tumors unveils novel cancer-relevant splicing networks , 2016, Genome research.

[33]  Yue Lu,et al.  Stem cell and neurogenic gene-expression profiles link prostate basal cells to aggressive prostate cancer , 2016, Nature Communications.

[34]  J. Shendure,et al.  Substantial inter-individual and limited intra-individual genomic diversity among tumors from men with metastatic prostate cancer , 2016, Nature Medicine.

[35]  K. Dalby,et al.  Longitudinal tracking of subpopulation dynamics and molecular changes during LNCaP cell castration and identification of inhibitors that could target the PSA−/lo castration-resistant cells , 2016, Oncotarget.

[36]  Matteo Benelli,et al.  Divergent clonal evolution of castration resistant neuroendocrine prostate cancer , 2016, Nature Medicine.

[37]  Robert Brown,et al.  TCGASpliceSeq a compendium of alternative mRNA splicing in cancer , 2015, Nucleic Acids Res..

[38]  Steven J. M. Jones,et al.  The Molecular Taxonomy of Primary Prostate Cancer , 2015, Cell.

[39]  J. Rinn,et al.  A comparison of genetically matched cell lines reveals the equivalence of human iPSCs and ESCs , 2015, Nature Biotechnology.

[40]  Yeon Jeong Kim,et al.  Intron retention is a widespread mechanism of tumor-suppressor inactivation , 2015, Nature Genetics.

[41]  Sarah J. Kurley,et al.  The spliceosome is a therapeutic vulnerability in MYC-driven cancer , 2015, Nature.

[42]  Jiaoti Huang,et al.  Systematic dissection of phenotypic, functional, and tumorigenic heterogeneity of human prostate cancer cells , 2015, Oncotarget.

[43]  H. Dvinge,et al.  Widespread intron retention diversifies most cancer transcriptomes , 2015, Genome Medicine.

[44]  Lawrence D. True,et al.  Integrative Clinical Genomics of Advanced Prostate Cancer , 2015, Cell.

[45]  Gael P. Alamancos,et al.  Leveraging transcript quantification for fast computation of alternative splicing profiles , 2014, bioRxiv.

[46]  P. Sharp,et al.  Detained introns are a novel, widespread class of post-transcriptionally spliced introns , 2015, Genes & development.

[47]  Lan Lin,et al.  rMATS: Robust and flexible detection of differential alternative splicing from replicate RNA-Seq data , 2014, Proceedings of the National Academy of Sciences.

[48]  B. Frey,et al.  Widespread intron retention in mammals functionally tunes transcriptomes , 2014, Genome research.

[49]  Yi Xing,et al.  Transcriptome-wide Landscape of Pre-mRNA Alternative Splicing Associated with Metastatic Colonization , 2014, Molecular Cancer Research.

[50]  Dan Chen,et al.  The splicing factor RBM4 controls apoptosis, proliferation, and migration to suppress tumor progression. , 2014, Cancer cell.

[51]  Wei Li,et al.  Whole Transcriptome Sequencing Reveals Extensive Unspliced mRNA in Metastatic Castration-Resistant Prostate Cancer , 2014, Molecular Cancer Research.

[52]  A. Chinnaiyan,et al.  Heterogeneity in the inter-tumor transcriptome of high risk prostate cancer , 2014, Genome Biology.

[53]  Chris Sander,et al.  Copy number alteration burden predicts prostate cancer relapse , 2014, Proceedings of the National Academy of Sciences.

[54]  Andreas Heger,et al.  Next-generation Sequencing of Advanced Prostate Cancer Treated with Androgen-deprivation Therapy , 2014, European urology.

[55]  Yael Mandel-Gutfreund,et al.  RBPmap: a web server for mapping binding sites of RNA-binding proteins , 2014, Nucleic Acids Res..

[56]  Zhaohui S. Qin,et al.  Therapeutic Targeting of BET Bromodomain Proteins in Castration-Resistant Prostate Cancer , 2014, Nature.

[57]  Hua Yu,et al.  Loss of androgen receptor expression promotes a stem-like cell phenotype in prostate cancer through STAT3 signaling. , 2014, Cancer research.

[58]  Joel S Parker,et al.  Variation in chromatin accessibility in human kidney cancer links H3K36 methyltransferase loss with widespread RNA processing defects , 2014, Genome research.

[59]  Jian Zhang,et al.  Misregulation of pre-mRNA alternative splicing in cancer. , 2013, Cancer discovery.

[60]  F. J. Ramos,et al.  Phase I Pharmacokinetic and Pharmacodynamic Study of the First-in-Class Spliceosome Inhibitor E7107 in Patients with Advanced Solid Tumors , 2013, Clinical Cancer Research.

[61]  Brendan J. Frey,et al.  A compendium of RNA-binding motifs for decoding gene regulation , 2013, Nature.

[62]  R. Davuluri,et al.  Isoform level expression profiles provide better cancer signatures than gene level expression profiles , 2013, Genome Medicine.

[63]  Benjamin E. Gross,et al.  Integrative Analysis of Complex Cancer Genomics and Clinical Profiles Using the cBioPortal , 2013, Science Signaling.

[64]  A. Sivachenko,et al.  Punctuated Evolution of Prostate Cancer Genomes , 2013, Cell.

[65]  Jiaoti Huang,et al.  The PSA(-/lo) prostate cancer cell population harbors self-renewing long-term tumor-propagating cells that resist castration. , 2012, Cell stem cell.

[66]  A. Sivachenko,et al.  Exome sequencing identifies recurrent SPOP, FOXA1 and MED12 mutations in prostate cancer , 2012, Nature Genetics.

[67]  Benjamin J. Raphael,et al.  The Mutational Landscape of Lethal Castrate Resistant Prostate Cancer , 2016 .

[68]  D. Tang,et al.  Understanding cancer stem cell heterogeneity and plasticity , 2012, Cell Research.

[69]  Hiroshi Tanaka,et al.  Alternative splicing of CD44 mRNA by ESRP1 enhances lung colonization of metastatic cancer cell , 2012, Nature Communications.

[70]  Stephen J. Salipante,et al.  Exome sequencing identifies a spectrum of mutation frequencies in advanced and lethal prostate cancers , 2011, Proceedings of the National Academy of Sciences.

[71]  K. Kelnar,et al.  The microRNA miR-34a inhibits prostate cancer stem cells and metastasis by directly repressing CD44. , 2011, Nature medicine.

[72]  C. Sander,et al.  Integrative genomic profiling of human prostate cancer. , 2010, Cancer cell.

[73]  G. Dreyfuss,et al.  Rapid-Response Splicing Reporter Screens Identify Differential Regulators of Constitutive and Alternative Splicing , 2010, Molecular and Cellular Biology.

[74]  A. Regev,et al.  An embryonic stem cell–like gene expression signature in poorly differentiated aggressive human tumors , 2008, Nature Genetics.

[75]  A. Jemal,et al.  Cancer statistics, 2019 , 2019, CA: a cancer journal for clinicians.

[76]  Michael R Hamblin,et al.  CA : A Cancer Journal for Clinicians , 2011 .